Novitium Pharma LLC
General
Total Cases14
Active Cases3
Patents3
Ratings
Experience
Grade
Trend
DCT
L1
B
PTAB
--
--
--
CAFC
--
--
--
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 12/30/24 | Summons Issued as to Novitium Pharma LLC on 12/27/2024. (jfm) (Entered: 12/30/2024) | |
| 12/30/24 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Rosemont Pharmaceuticals Inc., Other Affiliate Rosemont Pharmaceuticals Limited for Athena Bioscience, LLC filed by Athena Bioscience, LLC. (jfm) (Entered: 12/30/2024) | |
| 12/30/24 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US11103452 B2; US11752103 B2. (jfm) (Entered: 12/30/2024) | |
| 12/30/24 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/19/2024. Date of Expiration of Patent: 09/01/2040.Thirty Month Stay Deadline: 5/19/2027. (jfm) (Entered: 12/30/2024) | |
| 12/30/24 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) (Entered: 12/30/2024) | |
| 12/30/24 | COMPLAINT for Patent Infringement against Novitium Pharma LLC (Filing fee $ 405, receipt number ADEDC-4578769) - filed by Athena Bioscience, LLC. (Attachments: # [1] Exhibit A, # [2] Exhibit B, # [3] Civil Cover Sheet)(jfm) (Entered: 12/30/2024) | |
| 11/04/24 | NOTICE OF SERVICE of Plaintiffs' Second Set of Interrogatories (Nos. 9-10) to AET Pharma US, Inc. filed by Bioprojet Pharma SAS, Bioprojet Societe Civile de Recherche, Harmony Biosciences, LLC.(Tigan, Jeremy) (Entered: 11/04/2024) | |
| 11/04/24 | CONSENT JUDGMENT between Plaintiffs and Defendants Novugen Pharma (USA) LLC, Novugen Pharma Sdn. Bhd. (*Party Novugen Pharma (USA) LLC and Novugen Pharma Sdn. Bhd. terminated). Signed by Judge Jennifer L. Hall on 11/4/2024. (ceg) (Entered: 11/04/2024) | |
| 11/01/24 | NOTICE OF SERVICE of Bionpharma's Summary of Its Planned Expert Testimony, Reply Expert Report of R. Christian Moreton, Ph.D. on the Objective Baselessness of Plaintiff Azurity's Patent Infringement Claims in the First, Second and Third Wave Suits, Reply Expert Report of Bret M. Dickey, Ph.D. and Reply Expert Report of Nancy J. Linck, Ph.D. filed by Bionpharma Inc..(Haney, Megan) (Entered: 11/01/2024) | |
| 11/01/24 | ORDER: Defendant's Motion to Strike (D.I. [549] ) is GRANTED IN PART and DENIED IN PART such that, Dr. Mahan's report is STRICKEN, and the Motion is otherwise DENIED without prejudice. (See Order for further details) Signed by Judge Mitchell S. Goldberg on 11/1/2024. (mpb) (Entered: 11/01/2024) |